Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline's Nicoderm CQ will be second transdermal patch on market.

This article was originally published in The Tan Sheet

Executive Summary

OTC NICODERM CQ WILL BE ON STORE SHELVES BY LABOR DAY following the Aug. 2 FDA approval of the transdermal nicotine replacement therapy, SmithKline Beecham and Hoechst Marion Roussel jointly announced in a same-day release. The companies are touting Nicoderm CQ ("committed quitters") as "the first and only OTC nicotine patch to be available in all prescription strengths: 21 mg, 14 mg and 7 mg per day." The product trails McNeil's transdermal Nicotrol patch to the over-the-counter market by about a month and a half ("The Tan Sheet" July 8, p. 1).

Related Content

Topics

UsernamePublicRestriction

Register

PS085892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel